Racial and Ethnic Disparities and Health Inequities in Prostate CancerPremiere Date: Tuesday, October 25, 2022
This activity offers CE credit for:%>
- Certified Case Managers (CCMC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Dietetic Registration (CDR)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, October 25, 2025
|Edith Peterson Mitchell, MD, MACP, FCPP, FRCP (Moderator)
Clinical Professor of Medicine and Medical Oncology
Department of Medical Oncology
Director, Center to Eliminate Cancer Disparities
Associate Director, Diversity Affairs
Sidney Kimmel Cancer Center at Jefferson
116th President of the National Medical Association
|Randy A. Vince Jr., MD
Case Western Reserve University and University Hospitals
Director of Minority Men's Health
Cutler Men's Health Center
Racial and ethnic disparities in prostate cancer are well documented. Compared with White males, Black males have a 1.5 times higher chance of developing prostate cancer and 2.2 times higher likelihood of death resulting from the disease. Gaps in early diagnosis, treatment options and access, and survival rate remain for racial and ethnic underserved populations. A culmination of biases, disparities, and inequities continues a cycle of inadequate oncological treatment for prostate cancer, thus resulting in delayed diagnosis and suboptimal clinical management, prognosis, and survival rate.
In this CME Outfitters podcast, expert faculty will review recent data and discuss the impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with prostate cancer. This program will set the stage for intervention, empowering attendees to recognize and consider factors to improve prostate cancer treatment.
At the end of this CE activity, participants should be able to:
- Understand and acknowledge the influence of bias, disparities, and inequities on prostate cancer care.
Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.
Physicians, PAs, nurse practitioners, nurses, pharmacists, and dietitians, specializing in oncology, or involved in treating patients with prostate cancer.
CCMC Credit (Certified Case Managers):
This program has been approved for 0.5 CE credits by the Commission for Case Manager Certification (CCMC).
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning formats: Enduring material
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Dr. Mitchell reports the following financial relationships:
Advisory Board: Corvus Pharmaceuticals, Inc.
Consultant: Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Genentech, Inc.; and SEMA4 OpCo, Inc.
Dr. Vince reports no financial relationships to disclose.
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).